MGI, Barr Laboratories Inc. sales and marketing update

MOGN will exclusively distribute in the U.S. BRL's Mylocel oral tablet formulation of hydroxyurea, an antineoplastic agent to treat chronic myelocytic leukemia, carcinomas of the ovary and head and ne...